For example, Kanimura and colleagues have trialed IL-2/anti-IL-2 complex treatment in a mouse model of B16 melanoma [38], and Tomala and colleagues in a mouse model of BCL1 leukemia [39] as cancer immunotherapy. Here, IL2 is linked to melanoma.